Marshall Wace
EPRX icon

Marshall Wace’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Marshall Wace’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Hold
158,133
– – ﹤0.01% 2169
2026
Q1 		$1.14M Hold
158,133
– – ﹤0.01% 2072
2025
Q4 		$1.19M Buy
+158,133
New +$975K ﹤0.01% 1845

Other funds holding EPRX

Beutel, Goodman & Co
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Scotia Capital
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PFM Health Sciences
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Marshall Wace's EPRX Position: Q2 2026 in Review

Marshall Wace held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 158,133 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Marshall Wace first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Marshall Wace held 158,133 shares of Eupraxia Pharmaceuticals worth $1.05M as of Q2 2026.
  • Marshall Wace left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2169 holding.
  • Marshall Wace first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Marshall Wace's Eupraxia Pharmaceuticals position peaked at $1.19M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.